Contagion

Contagion is a London-based biotechnology company developing a proprietary platform for the delivery of programmable genetic medicines. Founded as a spin-out from University College London (UCL), the company focuses on a novel DNA-based delivery system designed to overcome the limitations of current viral and lipid nanoparticle vectors. The platform is engineered to provide high-precision targeting for infectious diseases and oncology, enabling the body to produce therapeutic proteins in situ. Contagion's technology aims to be modular and scalable, allowing for the rapid development of vaccines and therapies against emerging pathogens and complex cancers. The company is currently in the pre-clinical stage, advancing its lead programs toward clinical validation.